SCPMG is expected to join Quintiles’ three other prime sites into clinical research. Clinical research professionals from both Quintiles and SCPMG are expected to work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site.
The biopharmaceutical companies sponsoring trials are expected to benefit from collaboration between clinicians and research professionals, and processes for reducing complexity and accelerating trials.
Adam Chasse, head of global prime sites at Quintiles, said: “Quintiles undertakes more clinical research and that is why our customers rely on us to help them navigate risk and seize opportunity in this new landscape.
“It is therefore critical that we develop alliances with healthcare providers that share our focus on developing new and better medicines. Kaiser Permanente’s background in clinical, epidemiologic, and translational research is a natural fit with Quintiles’ core capabilities.”
Donald Fong, director of clinical trials of department of research and evaluation for SCPMG at Kaiser Permanente Southern California, said: “The Southern California Permanente clinical trials program works on the premise that all clinical trials research should focus on advancing the practice of medical care to improve health outcomes through designed and executed trials.
“Southern California Permanente Clinical Trial investigators are practicing physicians who use their clinical acumen and methodological training to bridge the gap between basic research and clinical practice. Typically, clinical trials research in Kaiser Permanente is aimed at evaluating the impact of interventions at the bedside. This perspective ensures that trials address meaningful questions.”